News & Updates
Filter by Specialty:

SC dose escalation restores efficacy of infliximab in IBD patients
17 Feb 2025
byStephen Padilla
Escalating the dose of subcutaneous (SC) CT-P13, a biosimilar of infliximab, from 120 to 240 mg every 2 weeks appears to bring back the efficacy of the drug in patients with inflammatory bowel disease (IBD) who no longer respond to treatment, suggests a study presented at 2025 Crohn's & Colitis Congress.